Detalhe da pesquisa
1.
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)â.
Ann Oncol
; 32(4): 533-541, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33482247
2.
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Ann Oncol
; 29(3): 758-765, 2018 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29216400
3.
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Ann Oncol
; 28(12): 3000-3008, 2017 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28950372
4.
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study.
Breast Cancer Res Treat
; 163(3): 507-515, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28324265
5.
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Acta Oncol
; 56(1): 88-92, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27838944
6.
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Gynecol Oncol
; 142(1): 89-94, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27012429
7.
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Gynecol Oncol
; 142(1): 95-101, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-27208537
8.
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Ann Oncol
; 25(3): 719-724, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24504442
9.
Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.
Ann Oncol
; 25(12): 2425-2432, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25294887
10.
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Ann Oncol
; 30(2): 344, 2019 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29741569
11.
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Br J Cancer
; 107(4): 639-45, 2012 Aug 07.
Artigo
Inglês
| MEDLINE | ID: mdl-22805326
12.
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study.
Br J Cancer
; 104(10): 1544-50, 2011 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-21505457
13.
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
Ann Oncol
; 22(6): 1266-1272, 2011 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21183581
14.
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Ann Oncol
; 22(5): 1054-1061, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21059637
15.
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).
Ann Oncol
; 19(7): 1304-1307, 2008 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-18417462
16.
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer.
Cancer Chemother Pharmacol
; 61(4): 579-85, 2008 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17520255
17.
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.
Eur J Cancer
; 94: 187-198, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29574364
18.
European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Clin Oncol (R Coll Radiol)
; 30(7): 448-454, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29550245
19.
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Eur J Cancer
; 43(6): 1017-22, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17336054
20.
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
Eur J Cancer
; 42(12): 1768-74, 2006 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16815702